Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

We report the results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/Dex) as initial therapy for myeloma. Thirtyfour patients were enrolled. Lenalidomide was given orally 25 mg daily on days 1 to 21 of a 28-day cycle. Dexamethasone was given orally 40 mg daily on days 1 to 4, 9 to 12,...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Rajkumar, S. Vincent, Hayman, Suzanne R., Lacy, Martha Q., Dispenzieri, Angela, Geyer, Susan M., Kabat, Brian, Zeldenrust, Steven R., Kumar, Shaji, Greipp, Philip R., Fonseca, Rafael, Lust, John A., Russell, Stephen J., Kyle, Robert A., Witzig, Thomas E., Gertz, Morie A.
التنسيق: Artigo
اللغة:Inglês
منشور في: © 2005 by The American Society of Hematology 2005
الموضوعات:
Clinical Trials and Observations
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895238/
https://ncbi.nlm.nih.gov/pubmed/16118317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-07-2817
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة